{"analyses":[{"ciLowerLimit":"-16.36","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"5.44","groupDescription":"Number of Participants With HI","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.320","pValueComment":"P-value was obtained from a stratified Cochran-Mantel-Haenszel chi-square test.","paramType":"Absolute Rate Difference","paramValue":"-5.46","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"70"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"163"}],"units":"Participants"}],"description":"Disease responses for HR MDS/CMML based on Modified IWG Response Criteria for MDS. HI: Hgb increase \\>=1.5 g/dL if baseline \\<11 g/dL; pl increase \\>=30\\*10\\^9/L if baseline \\>20\\*10\\^9/L or increase from \\<20\\*10\\^9/L to \\>20\\*10\\^9/L by at least 100%; neutrophil increase by 100% and absolute increase of \\>0.5\\*10\\^9/L if baseline \\<1.0\\*10\\^9/L.","groups":[{"description":"Participants were administered azacitidine 75 mg/m\\^2 IV or SC injection on Days 1 to 5, Days 8 and 9, in 28-day treatment cycles until disease progression or unacceptable toxicity or up to a maximum of 63 cycles.","id":"OG000","title":"Azacitidine 75 mg/m^2"},{"description":"Participants were administered azacitidine 75 mg/m\\^2 IV or SC injection on Days 1 to 5, Days 8 and 9 and pevonedistat 20 mg/m\\^2 IV infusion, on Days 1, 3, and 5 in 28-day treatment cycles until disease progression or unacceptable toxicity or up to a maximum of 63 cycles.","id":"OG001","title":"Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"REP included all participants who received at least 1 dose of study drug and had a baseline and at least 1 postbaseline disease assessment. Overall number analyzed is the number of participants with data available for analyses.","reportingStatus":"POSTED","timeFrame":"From randomization until HI (up to approximately 42 months)","title":"Number of Participants With Hematologic Improvement (HI)","type":"SECONDARY","unitOfMeasure":"Participants"}